Mihai Miron, owner of Ropharma Bra[ov (RPH) pharmaceutical company, transferred yesterday to the first tier of the BSE, believes Romania’s pharmaceutical market is currently the most dynamic in the region, and is likely to reach a level of around 10bn euros in the next seven years should state authorities keep their pledges about the healthcare sector.
“In Romania, unfortunately, the average expenses per capita for drugs stand at 100 euros, while the European average goes beyond 500 euros. We have a lot of catching up to do, and under the circumstances, my projections show the market could go as high as 10bn euros in the next seven years,” Miron stated.
At present, the pharmaceutical product market revolves around 2bn euros and in terms of value it is still on the rise despite the crisis.
Miron explained the level of the state’s healthcare expenditures was set to rise considering the Government has pledged to raise the minimum salary in the following years, with employees’ and employers’ contributions for healthcare poised to go up implicitly.
As far as his business is concerned, the Ropharma Bra[ov majority shareholder says the arrearage in the healthcare system has not affected it that much as he has financing available “under very good terms for this market.” Miron says he has a line of credit with an interest rate of 2.5% above EURIBOR (that is 3.5% a year), considering some local banks are paying 4% for euro deposits.

Subiecte #Mihai Miron#pharmaceutical market#Ropharma